Company Dossier · Health Care
West Pharmaceutical Services
- S&P 500
- Russell 1000
What West Pharmaceutical Services is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $3.33 billion, up 13% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.44 billion, up 29% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.23 billion, down 30% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.13 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 23, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.75 of 1.Palanor Discourse
- Latest annual report (filed February 17, 2026): 2 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $5.4 million on the open market.SEC Form 4
- 835 institutional managers reported a position at June 30, 2026 (+80 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 7 (2 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What West Pharmaceutical Services is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Retrenching · Mixed
Expanding ↔ Retrenching
Retrenching
- Capital spending4th pct
- Debt raised—
- Buybacks vs capex29th pct
- Hiring filings3rd pct
- Deals and private raises49th pct
- Patent publications64th pct
Confident ↔ Hedging
Mixed
- Call sentiment89th pct
- Call confidence54th pct
- Guidance changes57th pct
- Risk factors added26th pct
- Insider open-market trades39th pct
- + Call sentiment
- − Risk factors added
- + Guidance changes
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver45th pct
- Stress filings93rd pct
Credit
How these are built →West Pharmaceutical Services's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$0.2B
- Due within a year $0.0B
- Longer term $0.2B
- Default point $0.1B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name West Pharmaceutical Services, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralWest Pharmaceutical Services Needs Faster Earnings Growth To Justify Its Price (NYSE:WST)
seekingalpha.com · via Marketaux · Oct 8, 2026
- NeutralWest Pharma Stock: Still A Buy, But Expectations Are Rising (NYSE:WST)
seekingalpha.com · via Marketaux · Oct 7, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 19, 2026LobbyingLobbying report (CLARK HILL PUBLIC STRATEGIES LLC)third_quarter 2026 · $0.0 million
- Sep 22, 2026Patent
- Aug 18, 2026Patent
- Jul 21, 2026Patent
- Jul 18, 2026LobbyingLobbying report (CLARK HILL PUBLIC STRATEGIES LLC)second_quarter 2026 · $0.1 million
- Jul 14, 20268-KMaterial agreement signedItem 1.01
- Jun 30, 2026Patent
- Jun 16, 2026PatentPatent granted: MULTI-STAGE INJECTION DEVICEUS 12653966
- Jun 1, 20268-KDirector or officer changeItem 5.02
- May 20, 20268-KCybersecurity incidentItem 1.05
- May 11, 20268-KCybersecurity incidentItem 1.05
- May 5, 20268-KShareholder vote resultsItem 5.07
- Apr 18, 2026LobbyingLobbying report (CLARK HILL PUBLIC STRATEGIES LLC)first_quarter 2026 · $0.1 million
- Mar 9, 20268-KDirector or officer changeItem 5.02
- Feb 17, 202610-KAnnual report (10-K)2 risk factors added, 0 removed
- Jan 20, 2026LobbyingLobbying report (CLARK HILL PUBLIC STRATEGIES LLC)fourth_quarter 2025 · $0.1 million
- Oct 20, 2025LobbyingLobbying report (CLARK HILL PUBLIC STRATEGIES LLC)third_quarter 2025 · $0.1 million
- Sep 11, 20258-KDirector or officer changeItem 5.02
- Jul 21, 20258-KDirector or officer changeItem 5.02
- Jul 21, 2025LobbyingLobbying report (CLARK HILL PUBLIC STRATEGIES LLC)second_quarter 2025 · $0.1 million
- Jul 2, 2025Risk event
- May 12, 20258-KDirector or officer changeItem 5.02
- May 8, 20258-KShareholder vote resultsItem 5.07
- Apr 24, 20258-KDirector or officer changeItem 5.02
- Apr 21, 2025LobbyingLobbying report (CLARK HILL PUBLIC STRATEGIES LLC)first_quarter 2025 · $0.1 million
- Apr 14, 20258-KDirector or officer changeItem 5.02
- Mar 11, 20258-KDirector or officer changeItem 5.02
- Feb 28, 2025LobbyingLobbying report (CLARK HILL PUBLIC STRATEGIES LLC)first_quarter 2025
- Feb 18, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Dec 11, 20248-KDirector or officer changeItem 5.02
- Feb 20, 202410-KAnnual report (10-K)1 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Envista NVST | $2.9B | $0.3B | Jul 3, 2026 |
| Align Technology ALGN | $4.1B | $0.6B | Jun 30, 2026 |
| Cooper Companies (The) COO | $4.2B | $0.7B | Jul 31, 2026 |
| Neurocrine Biosciences NBIX | $3.4B | $0.6B | Jun 30, 2026 |
| BioMarin Pharmaceutical BMRN | $3.4B | $0.7B | Jun 30, 2026 |
| Veeva Systems VEEV | $3.5B | — | Jul 31, 2026 |
| Bruker BRKR | $3.5B | $0.1B | Jun 30, 2026 |
| United Therapeutics UTHR | $3.1B | $1.1B | Jun 30, 2026 |
Identity
- SEC CIK
- 105770
- Wikidata
- Q124358903
- SAM UEI
- JP72MQBU2RJ4